Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Sermorelin | Tesamorelin |
|---|---|---|
| Class | GHRH analogue | GHRH analogue |
| Research category | GH / IGF-1 axis | visceral fat and lipodystrophy |
| Evidence level | Moderate | High |
| Overall status | Previously approved (Rx); original product discontinued | Approved (Rx, US) — HIV-associated abdominal fat excess |
| FDA | Previously approved; discontinued | Approved (Rx) |
| EMA | Not approved | Application withdrawn |
| WADA | Prohibited — S2 | Prohibited — S2 |
| Mechanism studied | Sermorelin → GHRH receptor → Pulsatile GH → IGF-1 | Tesamorelin → GHRH receptor → Endogenous GH / IGF-1 → Visceral fat endpoints |
| Molecular weight | 3,357.9 g/mol | 5,136 g/mol |
| Sizes in stock | Not currently listed | 5mg, 10mg, 20mg |
Where the research overlaps
Both compounds are studied within GH Axis research. Sermorelin is classed as ghrh analogue, while Tesamorelin is ghrh analogue. Evidence is rated moderate for Sermorelin and high for Tesamorelin.
For a full write-up, read GHRH Analogues: Tesamorelin, Sermorelin and CJC-1295.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.